Pharmaceuticals

Nexletol Market Forecast: How Big Will It Be by 2030?

February 17, 2026February 17, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the nexletol market from 2026–2035 with trusted insights from The Business Research Company

Across 2026–2030, what is the expected market valuation path of the Nexletol Market?

The nexletol market size has experienced significant expansion in recent years. It is projected to increase from $3.21 billion in 2025 to $3.65 billion in 2026, achieving a compound annual growth rate (CAGR) of 13.8%. The historical growth of this market can be linked to factors such as limited cholesterol-lowering drug options, the high prevalence of hyperlipidemia, continued reliance on statin therapies, a rise in hospital and clinic prescriptions, and growing awareness of cardiovascular risks.

The nexletol market is projected for significant expansion in the coming years, with its valuation anticipated to reach $6.07 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 13.5%. This expansion during the projection period stems from factors such as the introduction of bempedoic acid-based treatments, the broadening reach of medication delivery in homecare and long-term care settings, an increase in cardiovascular disease cases, a heightened emphasis on combination treatment approaches, and the improvement of healthcare facilities in developing economies. Key trends anticipated during this period involve a greater uptake of LDL-C lowering therapies, a shift towards oral medication over injectable methods, the expansion of initiatives to raise awareness about cardiovascular disease, enhanced availability of both prescription and over-the-counter drugs, and the integration of homecare and long-term care environments for medication management.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24621&type=smp

Which Drivers Are Supporting The Rise Of The Nexletol Market?

The rising incidence of cardiovascular diseases is projected to drive the expansion of the nexletol market in the future. Cardiovascular diseases encompass a range of conditions impacting the heart and blood vessels, such as coronary artery disease, heart failure, and stroke. The increase in cardiovascular diseases can be attributed to increasingly sedentary lifestyles, where insufficient physical activity contributes to weight gain, metabolic imbalances, and elevated blood pressure, collectively heightening the risk of heart ailments. Nexletol offers benefits for cardiovascular diseases by reducing low-density lipoprotein (LDL) cholesterol levels, thereby assisting in the decrease of plaque accumulation in arteries and mitigating the likelihood of heart attacks and other cardiovascular events. As an illustration, in January 2024, data from the American Heart Association, a US-based non-profit body, revealed that the age-adjusted mortality rate from cardiovascular disease climbed to 233.3 per 100,000 in 2024, representing an increase of 4.0% from 224.4 per 100,000 in 2023. Consequently, the rising instances of cardiovascular diseases are anticipated to stimulate the expansion of the nexletol market.

What Leading Segments Are Studied In The Nexletol Market?

The nexletol market covered in this report is segmented –

1) By Type: 180mg, Other Types

2) By Administration Route: Oral, Injectable, Intravenous

3) By Indication: Hyperlipidemia, Atherosclerosis, Cardiovascular Disease

4) By End User: Hospitals, Clinics, Homecare Settings

Subsegments:

1) By 180 mg: Prescription-based, Over-The-Counter (OTC), Hospital or clinic use, Long-Term care facilities use

2) By Other Types: 40 mg, 80 mg, Other doses

Which Trends Are Influencing The Performance And Direction Of The Nexletol Market?

Companies operating within the nexletol market are increasingly prioritizing the creation of novel oral non-statin LDL-cholesterol lowering treatments, such as bempedoic acid-based agents, to meet the rising demand driven by the shortcomings of statins. Bempedoic acid–based agents are oral medications that reduce cholesterol by inhibiting ATP citrate lyase (ACL), an enzyme involved in the liver’s cholesterol-production process, leading to a decrease in LDL cholesterol. These agents assist patients, especially those intolerant to statins, by lowering LDL-C through a liver-specific mechanism that circumvents the muscle-related side effects often linked to conventional statins. For example, in March 2024, Esperion Therapeutics, Inc., a U.S.-based biopharmaceutical company, received FDA approval for a significant label expansion for its drugs Nexletol (bempedoic acid) and Nexlizet (bempedoic acid + ezetimibe). This approval allows their use for reducing cardiovascular risk and lowering LDL-C in both primary and secondary prevention settings, regardless of concurrent statin use. Nexletol is a once-daily oral tablet formulated with bempedoic acid; it works by inhibiting ACL to reduce LDL-C and inflammation, has demonstrated reductions in major cardiovascular events in the CLEAR Outcomes trial, and presents a distinct, non-statin oral option with a favorable safety profile. The updated label substantially increases U.S. patient eligibility, thereby bolstering market adoption.

Which Major Firms Are Strengthening Their Position In The Nexletol Market?

Major companies operating in the nexletol market are Esperion Therapeutics Inc., Daiichi Sankyo Company Limited, Otsuka Pharmaceutical Co. Ltd., Mitsubishi Tanabe Pharma Corporation, Recordati S.p.A., Almirall S.A., Menarini Group, Les Laboratoires Servier, Torrent Pharmaceuticals Ltd., Lupin Limited, Zydus Lifesciences Limited, Sun Pharmaceutical Industries Limited, Dr. Reddy’s Laboratories Limited, Cipla Limited, Aurobindo Pharma Limited, Intas Pharmaceuticals Limited, Glenmark Pharmaceuticals Limited, Alembic Pharmaceuticals Limited, Hetero Drugs Limited, Alkem Laboratories Limited, Wockhardt Limited, Mylan (Viatris Inc.), Teva Pharmaceutical Industries Limited, Apotex Inc., Hikma Pharmaceuticals PLC, Krka d.d., STADA Arzneimittel AG, Sandoz International GmbH

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/nexletol-global-market-report

Which Region Shows The Strongest Potential For Future Expansion In The Nexletol Market?

North America was the largest region in the nexletol market in 2025. The regions covered in the nexletol market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Nexletol Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24621&type=smp

Browse Through More Reports Similar to the Global Nexletol Market 2026, By The Business Research Company

Nematicides Market Report 2026

https://www.thebusinessresearchcompany.com/report/nematicides-global-market-report

Nebulizers Market Report 2026

https://www.thebusinessresearchcompany.com/report/nebulizers-global-market-report

Vertical Market Software Market Report 2026

https://www.thebusinessresearchcompany.com/report/vertical-market-software-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795